How much does a box of imported capmatinib cost? How much does a box of generic drugs cost?

Capmatinib (Capmatinib) is a targeted therapy drug that belongs to the category of kinase inhibitors. Its research and development purpose is to provide personalized and targeted treatment for patients with METexon14 skipping mutations in non-small cell lung cancer (NSCLC).

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive.

The generic drugs marketed abroad are much cheaper, mainly Lao generic drugs, which cost around 3,000 to 4,000 yuan, and the ingredients of the original drugs and generic drugs are basically the same.

METkinase is a receptor tyrosine kinase involved in regulating key biological processes such as cell growth, division, migration and survival. In METexon14 skipping mutant NSCLC patients, MET kinase is abnormally activated, promoting tumor development. The design concept of capmatinib is to inhibit the growth and spread of cancer cells by specifically inhibiting the activity of MET kinase and interfering with abnormal signaling pathways.

This oral drug has high selectivity through specific inhibition of MET kinase, and mainly affects MET exon 14 skipping mutant NSCLC patients. Clinical trial data show that capmatinib shows significant objective response rate and survival prolongation effect in this patient group, providing a new treatment option for patients.

When using capmatinib, patients need to closely cooperate with their doctor's monitoring and treatment plan to ensure optimal efficacy. Medications may cause a range of side effects, including fatigue, nausea, diarrhea, etc. Patients should promptly report any discomfort to their doctor. In addition, patients need to undergo regular medical examinations and follow-up visits during treatment to monitor the progression of the disease and evaluate the efficacy of the drug.